PNA-CPP Adjuvants for Mucosal Vaccine Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines, especially inactivated and subunit vaccines, face challenges in generating sufficient immunity due to lack of infectivity and mucosal affinity, requiring adjuvants with immunostimulatory capabilities, while existing adjuvants like aluminum salts have limitations, particularly in combination with mucosal vaccines.
Innovation Solution
Modification of peptide nucleic acids (PNAs) with cell penetrating peptides (CPPs), such as TAT from HIV, to create adjuvants that enhance vaccine efficacy and safety by promoting immune responses through both injection and mucosal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inactivated vaccines or subunit vaccines are used, then safety is improved, but immune response capability deteriorates
Solution Approach 1:
The patent combines inactivated/subunit vaccines (safe but weak immunogenicity) with PNA-CPP adjuvants (potent immunostimulatory agents) to create a composite vaccine system that maintains safety while significantly enhancing immune response capability through synergistic interaction between antigen and adjuvant
Solution Approach 2:
The invention creates a composite vaccine formulation consisting of inactivated or subunit antigen components combined with PNA-CPP adjuvant molecules, where the composite system produces immune responses superior to either component alone while maintaining the safety profile of the inactivated/subunit approach
2Productivity
If live attenuated vaccines are used, then immune response capability is improved, but safety deteriorates
Solution Approach 1:
The patent extracts the immunostimulatory function from live attenuated vaccines and transfers it to the PNA-CPP adjuvant system, allowing inactivated/subunit vaccines to achieve similar immune response capability without the safety risks associated with live viral components
3Productivity
If aluminum salts adjuvant is used, then immune response is improved, but mucosal affinity deteriorates
Solution Approach 1:
The patent fundamentally changes the chemical and physical parameters of the adjuvant system by using PNA-CPP molecules with specific properties (cell-penetrating capability, mucosal affinity, immunostimulatory activity) that enable effective immune response enhancement through mucosal routes, unlike traditional aluminum salt adjuvants
Data Source
AI summary
Provided are an adjuvant useful for preparing a vaccine having high efficacy and high safety, and a vaccine composition comprising the adjuvant.The adjuvant comprises a peptide nucleic acid to which a cell penetrating peptide is bound.